CLINICAL TRIALS PROFILE FOR AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

All Clinical Trials for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05646693 ↗	Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus	Recruiting	Hospital Civil de Guadalajara	Phase 2	2022-12-01	The main objective of our study is to evaluate the effect of combinated antioxidants therapy with Adepsique® (amitriptyline, perphenazine, and diazepam) on patients with tinnitus chronic symptoms, evaluating the levels of inflammatory cytokines and oxidative stress in blood. The researchers intend to include 58 patients, divided into two intervention groups, who will be randomly assigned a pill with antioxidants or placebo, and the patient must eat one pill per day for 3 months. In the study, the clinical characteristics of tinnitus, inflammatory cytokines and oxidative stress markers will be evaluated, before, during and after the intervention with antioxidant therapy. Subsequently, the clinical and sample results will be evaluated to compare the effects between them.
NCT05646693 ↗	Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus	Recruiting	Institute of Experimental and Clinical Therapeutics	Phase 2	2022-12-01	The main objective of our study is to evaluate the effect of combinated antioxidants therapy with Adepsique® (amitriptyline, perphenazine, and diazepam) on patients with tinnitus chronic symptoms, evaluating the levels of inflammatory cytokines and oxidative stress in blood. The researchers intend to include 58 patients, divided into two intervention groups, who will be randomly assigned a pill with antioxidants or placebo, and the patient must eat one pill per day for 3 months. In the study, the clinical characteristics of tinnitus, inflammatory cytokines and oxidative stress markers will be evaluated, before, during and after the intervention with antioxidant therapy. Subsequently, the clinical and sample results will be evaluated to compare the effects between them.
NCT05646693 ↗	Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus	Recruiting	University of Guadalajara	Phase 2	2022-12-01	The main objective of our study is to evaluate the effect of combinated antioxidants therapy with Adepsique® (amitriptyline, perphenazine, and diazepam) on patients with tinnitus chronic symptoms, evaluating the levels of inflammatory cytokines and oxidative stress in blood. The researchers intend to include 58 patients, divided into two intervention groups, who will be randomly assigned a pill with antioxidants or placebo, and the patient must eat one pill per day for 3 months. In the study, the clinical characteristics of tinnitus, inflammatory cytokines and oxidative stress markers will be evaluated, before, during and after the intervention with antioxidant therapy. Subsequently, the clinical and sample results will be evaluated to compare the effects between them.

Clinical Trial Conditions for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

Condition Name

Condition Name for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Intervention	Trials
Antioxidant Therapy	1
Inflammatory Cytokines	1
Oxidative Stress	1
Psychiatric Drugs	1

Condition MeSH

Condition MeSH for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Intervention	Trials
Tinnitus	1

Clinical Trial Locations for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

Trials by Country

Trials by Country for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Location	Trials
Mexico	1

Clinical Trial Progress for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

Clinical Trial Phase

Clinical Trial Phase for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Clinical Trial Phase	Trials
Recruiting	1

Clinical Trial Sponsors for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

Sponsor Name

Sponsor Name for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Sponsor	Trials
Hospital Civil de Guadalajara	1
Institute of Experimental and Clinical Therapeutics	1
University of Guadalajara	1

Sponsor Type

Sponsor Type for AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE
Sponsor	Trials
Other	3

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE Market Analysis and Financial Projection

Last updated: May 3, 2026

Clinical Trials Update, Market Analysis and Projections: Amitriptyline Hydrochloride + Perphenazine

What is the current clinical development status for amitriptyline hydrochloride + perphenazine?

No reliable, product-specific (fixed-dose or combination-specified) clinical trial pipeline update is available from the information provided. Without verifiable trial registry evidence tied to the exact combination (amitriptyline hydrochloride + perphenazine) and a current status date, a complete and accurate “clinical trials update” cannot be produced.

What is the commercial market structure for amitriptyline hydrochloride + perphenazine?

Amitriptyline hydrochloride is a tricyclic antidepressant. Perphenazine is a typical antipsychotic. The combination is used in clinical practice to address conditions where antidepressant and antipsychotic effects are combined, including treatment-resistant depression and psychotic depression, depending on region, labeling, and prescriber practice.

Because the combination is not a novel, high-profile single-agent platform, market sizing is typically reported at the class or country-product level (antidepressants, antipsychotics, and “combination products” where applicable), not as a standalone global revenue category for the specific amitriptyline + perphenazine pairing. A product-level revenue model for the exact combination requires country-level formulary penetration, reimbursement, and product availability data by strength/formulation and dosage form, which is not present in the input.

How should revenue and volume for the combination be projected given the available data?

No complete projection can be produced for the exact combination without:

• country-by-country access (approvals, reimbursed status, and formulary listing),
• pack-level pricing and volume,
• switching behavior driven by generic entry and competing antidepressant-antipsychotic strategies,
• and product-specific utilization assumptions by indication.

A projection that treats the combination as a single global revenue pool would be methodologically unsound without verifiable evidence on market share at the product level.

Market outlook drivers that typically move demand

Even without product-specific pipeline numbers, the demand drivers that generally affect this drug category are consistent:

• Generic penetration: both components face long-term generic availability, compressing branded pricing and shifting the market toward cost-minimized prescribing.
• Formulary and reimbursement: access depends more on local reimbursement rules than on incremental clinical trial activity.
• Treatment patterns: use depends on preference for alternative regimens (other antidepressants, atypical antipsychotics, and newer augmentation strategies).
• Safety and tolerability: anticholinergic and sedation burden (from amitriptyline) and extrapyramidal symptom risk (from perphenazine) influence clinician selection versus alternative agents.

Actionable commercial implications (what to do with the combination position)

Given the lack of verifiable combination-specific trial and market inputs, the only actionable path is to structure decision-making around substitution and access realities rather than pipeline upside:

• For R&D planners: treat the combination as a legacy regimen with limited commercial upside from incremental formulation unless there is evidence of clinically meaningful tolerability improvements or adherence benefits tied to a measurable regulatory or clinical endpoint.
• For investors: value the combination based on durable cash flows from generics and access stability, not on near-term “pipeline catalysts.”
• For BD and licensing: any partnership should target jurisdictional access (product registrations, tender inclusion, reimbursement) and manufacturing economics rather than assuming trial-driven market expansion.

What key metrics would support a defensible forecast (framework)

A defensible forecast for this specific combination requires the following inputs per market (country-level):

1. Market access: number of reimbursed listing channels and therapeutic interchange rules.
2. Utilization: prescription volume by strength and dosage form.
3. Pricing: average net price after rebates/tenders and typical pack size.
4. Competition: substitution by other antidepressant-antipsychotic combinations and guideline-aligned regimens.
5. Switching: time-to-generic entry and post-generic erosion curve by brand versus generic.

No such dataset is provided in the prompt, so a numerically grounded projection cannot be generated.

---

Key Takeaways

• A reliable clinical trials update for the specific combination amitriptyline hydrochloride + perphenazine cannot be produced from the provided information.
• A product-level market analysis and quantitative projection for the exact combination cannot be produced without country and product utilization and pricing inputs.
• The combination’s market behavior is mainly shaped by generic availability, formulary access, and prescriber substitution patterns, not by new clinical development signals.

---

FAQs

1. Is amitriptyline hydrochloride + perphenazine considered a fixed-dose combination globally?
   It depends on jurisdiction-specific product approvals and formulations; many markets rely on generic availability of the components and locally approved combination presentations.

2. What are the primary clinical rationale areas for combining these two drugs?
   Clinical use commonly aligns with psychotic depression and treatment-resistant depression where antidepressant and antipsychotic pharmacology are combined, subject to regional labeling and practice.

3. How do generic trends typically impact this combination’s economics?
   Generic entry usually compresses pricing, increases volume at lower net revenue per unit, and shifts value toward manufacturing scale and tender positioning.

4. What tends to drive payer and formulary decisions for legacy psych antidepressant regimens?
   Net cost, safety profile considerations relevant to local prescribing norms, therapeutic interchange policies, and guideline alignment.

5. What would count as a meaningful catalyst for this combination in the future?
   A regulatory filing that changes access (label expansion, new dosage form with differentiated tolerability) or a measurable shift in prescribing driven by updated treatment standards, supported by verifiable evidence.

---

References

[1] No sources were provided in the prompt.